Related Experiment Video
Updated: Apr 8, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES]
Clopidogrel resistance in cardiovascular patients is linked to coronary heart disease type, diabetes, and specific gene variations like CYP2C19*2 and TBS1. These factors increase the risk of cardiovascular events.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Clinical Pharmacology
Background:
- Clopidogogrel is a widely used antiplatelet medication for cardiovascular disease.
- Patient response to clopidogrel can vary significantly, leading to resistance.
- Understanding factors contributing to clopidogogrel resistance is crucial for optimizing patient outcomes.
Purpose of the Study:
- To identify clinical and pharmacological factors associated with clopidogrel resistance.
- To investigate the impact of genetic polymorphisms on clopidogrel resistance.
- To assess the relationship between clopidogrel resistance and cardiovascular events.
Main Methods:
- Analysis of clinical data from 250 cardiovascular disease patients over 18 months.
- Evaluation of factors including coronary heart disease type and carbohydrate metabolism.
- Genotyping for CYP2C19*2, CYP2C9, and TBS1 gene polymorphisms.
Main Results:
- Clopidogrel resistance risk is associated with coronary heart disease form, carbohydrate metabolism, and CYP2C19*2 (AA genotype) and TBS1 gene variants.
- Diabetics exhibiting clopidogrel resistance experienced significantly more cardiovascular events.
- Patients with absent CYP2C9 gene function (*2/*3 alleles) and AT/TT polymorphism in TBS1 also had increased cardiovascular events.
Conclusions:
- Coronary heart disease type, diabetes, and specific genetic markers (CYP2C19*2, TBS1) are key determinants of clopidogrel resistance.
- Genetic variations in CYP2C19, CYP2C9, and TBS1 influence clopidogrel efficacy and cardiovascular event risk.
- Personalized antiplatelet therapy based on genetic profiling may improve outcomes in cardiovascular patients.
More Related Videos
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug Toxicity: Risk factors
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Factors Affecting Drug Response: Overview
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

